// App-Quantinova.ai

580 : A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.

Researchers

Presenter

  • Khurum Hayat Khan

Principal Investigators

  • Mihaela Rata

  • Dow-Mu Koh

  • Nina Tunariu

  • David J. Collins

  • Ian Chau

  • David J. Watkins

  • Naureen Starling

  • Sheela Rao

  • Clare Peckitt

  • Nicos Fotiadis

  • Ruwaida Begum

  • Claire Saffery

  • Janet Thomas

  • Marco Gerlinger

  • Nicola Valeri

  • David Cunningham

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Translational Oncogenomics Lab, Institute of Cancer Research, London, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • 3β-hydroxysterol Δ24-reductase

  • Regenerating islet-derived 1 alpha

  • Apparent diffusion coefficient

Drug/Treatment

  • Regorafenib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved